Cambridge Molecular is pleased to announce the release of its latest target-specific virtual screening pipeline, DeepDELve 2. The announcement is the culmination of two and a half years of research and development.
DeepDELve is Cambridge Molecular’s DEL-powered virtual screening platform, built around a proprietary twinned deep learning and chemoinformatics workflow. The platform provides for a DEL-followup procedure that yields more diverse leads than a resynthesis paradigm, considerably faster and with an approximately 95% reduction in compound acquisition costs.
The original DeepDELve pipeline underwent a successful pilot project with X-Chem, Inc., a leading Boston-based DEL contract research organisation.
DeepDELve 2 incorporates significant upgrades to the original pipeline and is highly optimised for robustness, accuracy, diversity of output, and speed. It also incorporates a new diversity module, allowing for integrated selection of maximally diverse catalogue compounds with the highest possible confidence. After the completion of a one-off initial calibration project, recommendations are available within 24 hours of each DEL screen. The next version of DeepDELve will be significantly faster.
DeepDELve 2 is available for pilot projects to any team that generates or holds DEL data. Please contact us for more information.
Cambridge Molecular Ltd
The Bradfield Centre
184 Cambridge Science Park
Cambridge CB4 0GA